Kristin Highland

Dr. Kristin Highland

Pulmonary Medicine
26900 Cedar Road, 
Beachwood, OH 
On Staff At
Offers Telehealth
37 Years of Experience
26900 Cedar Road, 
Beachwood, OH 
OverviewInsuranceLocationsClinical Research

Overview

Kristin Highland is a Pulmonary Medicine provider in Beachwood, Ohio. Dr. Highland has been practicing medicine for over 37 years and is rated as an Experienced provider by MediFind in the treatment of Scleroderma. Her top areas of expertise are Interstitial Lung Disease, Acute Interstitial Pneumonia, Pulmonary Hypertension, Systemic Sclerosis (SSc), and Lung Transplant.

Her clinical research consists of co-authoring 74 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Indiana University, 1989.0
Residency
MUSC Medical Center of Medical University of South Carolina
Specialties
Pulmonary Medicine
Licenses
Internal Medicine in OH
Board Certifications
American Board Of Internal Medicine, 2012
Fellowships
MUSC Medical Center of Medical University of South Carolina
Hospital Affiliations
Cleveland Clinic
Hillcrest Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Beachwood Family Health and Surgery Center
26900 Cedar Road, Beachwood, OH 44122
Other Locations
Cleveland Clinic Main Campus
2049 East 100th Street, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
View 3 Less Clinical Trials

73 Total Publications

Corrigendum to ''Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)'' [J Heart Lung Transplant 43 (2024) 272-283].
Corrigendum to ''Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)'' [J Heart Lung Transplant 43 (2024) 272-283].
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: May 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Highland's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 8 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile